Archive for the ‘Diabetes Insulin’ Category

Animus Issues Urgent Recall Notice to Insulin Pump Users

Tuesday, November 22nd, 2011

Insulin pump

In a rare development that all insulin dependent diabetics should be aware of, Johnson & Johnson has recalled around 384,000 cartridges for its Animus Insulin Pump.

To date, twenty-two injuries have been reported as a result of faulty insulin pump cartridges leaking at the side where the plunger is. The leaks can result in the diabetic using the cartridge receiving a lower insulin dosage than they intended.

Johnson & Johnson has posted an urgent notice on their Animus division website warning consumers to check their cartridge supply and to stop using any of the 2.0 ml cartridges in question immediately. It is also contacting insulin pump users, or as they refer to them, “insulin pumpers”, that may have purchased the faulty cartridges, and shipping them replacement cartridges. The website notice reads in part:

Please note that under-delivery of insulin can cause high blood sugar and/or diabetic ketoacidosis. These are serious conditions that can cause severe health impact, including death. Symptoms of diabetic ketoacidosis may include nausea, vomiting, shortness of breath and excess thirst/urination. Contact your healthcare professional immediately if you are experiencing any of these symptoms.

Ketoacidosis usually develops slowly over 24 hours, starting with symptoms such as fatigue, mental stupor, decreased appetite, loss of appetite, headache, and fading consciousness. Other ketoacidosis symptoms all insulin dependent diabetics should be aware of include stomach or abdominal pain, a flushed complexion, and breath that smells like fruit or nail polish remover.

The insulin cartridge recall extends to the US and France. The recall applies only to lot numbers B201575, B201576, B201581, B201582 and B201583. The insulin pump cartridges in questions were shipped between November 30th, 2010 and January 4th, 2011.

Animas has provided the following instructions for insulin pumpers diabetics with a recalled insulin cartridge who need to disconnect their infusion sets:

1) Disconnect the infusion set from your body (failure to follow these important safety instructions can lead to unintended delivery of insulin).
2) Unscrew the cartridge cap, leaving the tubing connected to the cartridge.
3) With the tubing connected to the cartridge, pull the cartridge straight out of your insulin pump.
4) Disconnect tubing from cartridge, set the cartridge aside to return to Animas.
5) Fill a new cartridge from an unaffected lot not listed above, and attach infusion set tubing.
6) While still disconnected, rewind, load the cartridge and prime.
7) Connect tubing to site once prime is complete.
8) Fill cannula only if you have inserted a new infusion set.

Animas Customer Support can also be reached by phone toll-free at 877-937-7867.

Share

Eating Too Quickly Doubles the Risk of Insulin Resistance

Friday, November 18th, 2011

from Quasic

Yet another reason to listen to your mother and slow down and chew your food properly – eating too quickly has been associated with a doubled risk of developing impaired glucose tolerance, or pre-diabetes. As the name suggests, pre-diabetes is the forerunner to developing type 2 diabetes. Most diabetics have type 2 diabetes – a form of diabetes where your body no longer responds properly to insulin (called insulin resistance). Type 2 diabetes used to be described as non insulin dependent diabetes.

Insulin is the hormone that moves sugar (glucose) from the blood to the body’s cells to provide them with energy. If your cells do not use insulin properly, the pancreas produces more insulin that normal to cope with the body’s demands. Eventually, the pancreas cannot keep up, and excess glucose builds up in the bloodstream. Type 2 diabetes is characterized by high levels of glucose in the blood.

A recent Japanese study followed over 170 healthy individuals for three years, monitoring their eating habits. Snacking, eating late at night, skipping meals and eating out were not associated with developing pre-diabetes. The one and only eating habit associated with the development of insulin resistance was eating too quickly.

The researchers aren’t sure why eating faster makes an individual more likely to develop pre-diabetes and type 2 diabetes, but suspect that eating rapidly results in higher post-meal blood glucose levels. Some doctors also point out that eating too quickly results in an overall increase in the amount of calories taken in, and a resulting weight gain. Since it takes about 20 minutes for the brain to receive the signal that the stomach is full, those who eat quickly continue eating without realizing that their stomach is filled.

Previous research has also shown that eating quickly results in increased weight gain. Insulin resistance generally increases with increased body fat, and there is a pronounced connection between obesity and diabetes. The two are so closely connected that it gave rise to the term “diabesity”. Diabesity is currently epidemic across the developed world.

Insulin resistance has no symptoms. Pre-diabetes is sometimes called impaired glucose tolerance, and can be diagnosed with a fasting glucose test or a glucose tolerance test. The American Diabetes Association recommends that adults who are overweight and have one or more additional risk factors for diabetes should consider being tested. Additional risk factors include:

• Having a parent or sibling with diabetes
• Being physically inactive.
• Being African American, Alaska native, American Indian, Asian American, Hispanic or Latino, or a Pacific Islander
• Giving birth to a baby weighing more than 9 pounds or being diagnosed with gestational diabetes
• Having high blood pressure or being treated for high blood pressure
• Low HDL (“good”) cholesterol levels or high triglyceride levels
• Having polycystic ovary syndrome
• Having a history of cardiovascular disease

People with pre-diabetes can avoid becoming diabetic and having to take diabetes medication by losing weight, being physically active, eating a healthy diet, and, as we now know, not eating too quickly.

Share

What is Stiff-Person Syndrome?

Monday, September 12th, 2011

Immune boost from VidaScience

One very rare and unusual condition associated with diabetes is Stiff-Person syndrome, also referred to as Myotonic Dystrophy. Stiff-Person syndrome (SPS) is a central nervous system disorder characterized by severe muscle stiffness that travels from place to place in the trunk, arms and legs. SPS affects about 1 in 1 million Americans, and about 1 in 10,000 diabetics.

Someone with SPS is exceedingly hypersensitive to normal stimuli such as sound, touch and emotional stress. A sudden noise, tap or worry can trigger muscle spasms that distort the body into hunched over, stiff postures. People with SPS suffer from frequent falls when spasms are triggered by commonplace noises like a door slamming or a car horn. Because people with SPS lack normal protective reflexes, spasms and falls can result in serious injuries, including fractures, muscle tears and joint dislocations.

SPS is also referred to as “Stiff Man Syndrome”, although – like many autoimmune conditions – it is much more common in women than in men. SPS usually strikes between the ages of 30 and 50, but the syndrome can also occur as Stiff Baby Syndrome in children under three. Commonly, SPS begins with an exaggerated upright posture due to muscle stiffness in the lower back, and then moves into the legs. As the disease progresses the patient must move very slowly, as rapid movements can trigger severe spasms.

The unusual and unfortunate symptoms of SPS can be confused with those of fibromyalgia, Parkinson’s disease or multiple sclerosis. Sufferers may also be misdiagnosed as having an anxiety or psychosomatic disorder. A diagnosis of SPS is aided by the detection of elevated levels of the antibody glutamic acid decarboxylase (GAD), which is present in the cerebral spinal fluid of about 80% of SPS cases.

GAD antibodies tests are also an important diagnosis tool for diabetes mellitus. GAD tests are used to differentiate between types of diabetes, to predict the risk and track the progression of the disease, and to predict the need for insulin therapy in type 2 diabetics. GAD reduces the brain’s main inhibitory transmitter, GABA. It’s theorized that this reduction of GABA interferes with the modulation of spinal cord reflexes, resulting in the hyperactivity and hyperexcitabity that characterizes SPS.

SPS can be treated, but not cured. Symptoms can be eased with a combination of anti-anxiety medications, anti-convulsants, muscle relaxers and pain medication. A recent study proved intravenous immunoglobulin treatment (a therapy for autoimmune diseases and immune deficiencies) effective in reducing stiffness and hypersensitivity in patients with Stiff-Person syndrome. Another study using the arthritis drug rituximab led to disappointing results.

The cause of SPS remains a mystery, but it appears to be an out of kilter autoimmune response in the brain and spinal cord. SPS is associated with other autoimmune diseases such as diabetes, pernicious anemia, thyroiditis, and the skin disease vitiligo. The National Institute of Neurological Disorders and Stroke is continuing to both conduct and support research into SPS, focusing on uncovering the cause of this rare and curious condition.

Share

Insulin Inhaler to Replace Mealtime Insulin Injections?

Friday, September 2nd, 2011

Insulin Inhaler - AFREZZA

There’s good news for insulin dependent diabetics who rely on fast-acting mealtime insulin injections to keep their blood sugar under control. MannKind Corporation has the go-ahead to continue clinical testing of its investigational inhaled insulin, AFREZZA. The drug maker and the FDA met to confirm the protocols for two new studies, one in type 1 diabetics, and one in type 2 diabetics.

AFREZZA is an ultra-rapid acting inhaled insulin which uses patented technology to deliver powdered insulin from a thumb-sized device into the lungs. The lungs are an effective option for delivering diabetes medication, largely because of their huge surface area (about the size of a tennis court).
(more…)

Share

Weird Warning for Diabetic Pet Owners

Friday, August 5th, 2011

Photo Credit: Teachable Moments

The Director of the Amputation Prevention Center at the Valley Presbyterian Hospital in Van Nuys, Dr. Lee C. Rogers, has a warning for diabetic pet owners who have suffered a loss of feeling due to nerve damage.

The warning stems from an incident in which a two-year-old Jack Russell terrier chewed off the infected big toe of its owner while she slept. The 48-year-old Des Moines woman woke in the morning to find part of her toe missing, and blood on her bed and her pet’s face.
(more…)

Share

Lantus Vs. NPH

Tuesday, June 28th, 2011

NPH Vs. Lantus

What is Lantus? How does Lantus work?
Lantus (chemical name insulin glargine) is a newer insulin analogue used to treat both Type 1 and Type 2 Diabetes. Lantus is a long acting insulin and only needs to be injected once daily.

What is the difference between Lantus and other injectable insulin?
Lantus is a long acting insulin, it will have a duration of 24 hours or longer. Humalog has an immediate effect, within 10 minutes. Humulin R has an intermediate effect (within 2 hours), lasting for about 8 hours. While Humulin N also has an intermediate effect (within 2 hours and lasts for 18-24 hours). Lantus would be considered most similar to Humulin N (which is also injected at night). However one key difference exists, Lantus will have a much lower incidence of nocturnal hypoglycemia (falling of blood sugar during the night). This is because Lantus will have a steady release of insulin during 24 hours, while Humulin N will reach a much higher peak and then the peak blood level will fall. This results commonly in hypoglycemia (falling of blood sugar).
(more…)

Share

Insulin Shock Therapy Once Used to Treat Schizophrenia

Monday, June 6th, 2011

Insulin Shock Therapy

It’s not widely known that large doses of insulin were commonly used in psychiatric institutions in the 1940s and 1950s to treat schizophrenia and other mental illness. Insulin shock therapy was regarded as the treatment of choice for schizophrenia for about twenty years, enjoying uncritical acceptance in Europe and America.

The “treatment” was considered a type of shock therapy. Patients were given regular insulin injections to produce five or six diabetic comas a week for weeks at a time. Insulin therapy continued until the patient improved, or until 50 to 60 comas had been induced.

The originator of insulin shock therapy, also known as insulin coma therapy, was Dr. Manfred Sakel. The Polish doctor stumbled upon the therapy accidentally while working in Vienna, when a patient in whom he’d provoked an insulin coma showed a remarkable improvement in her mental functioning.

Sakel practiced and popularized insulin therapy in Europe, and introduced it to the US after he emigrated from Austria to New York in 1936. The practice of insulin dosing continued into the 1960s in America, and for much longer in countries like China and the former Soviet Union.

Sakel believed that the seizures and unconsciousness experienced by psychiatric patients undergoing an insulin-induced hypoglycemic episode resulted in dramatic change in their mental state. In his own words: “My supposition was that some noxious agent weakened the resilience and the metabolism of the nerve cells…blocking the cell off with insulin will force it to conserve functional energy and store it to be available for the reinforcement of the cell.”

To read more about Insulin Shock Therapy Once Used to Treat Schizophrenia, visit Long Acting Insulin blog.

Share

Numerous Non-Invasive Glucose Monitors under Development

Wednesday, May 11th, 2011


Diabetics will soon be able to keep track of their blood sugar without enduring multiple daily finger pricks. A number of non-invasive blood glucose monitors are on the horizon. Big Mounain Drugs is your first choice of Canadian pharmacy offering a variety of diabetes medications and diabetic insulin.

Diabetics are still awaiting a reliable, non-invasive means of blood glucose monitoring – one that doesn’t require breaking the skin or confirmation with a traditional monitoring method. The latest continuous glucose monitoring technology involves small sensors implanted in the skin that must be calibrated several times a day, and replaced every few days to a week to avoid infection. Because the blood sugar testers are implanted into the skin, the body sees the sensors as foreign objects, and frequently forms scar tissue around them.
(more…)

Share

Insulin Producing Cell Pouch Approaching Clinical Trials in Humans

Thursday, March 10th, 2011

Photo credit: ninci

A Canadian health sciences company focusing on innovative medical technology has successfully tested an organ-like device containing insulin producing islet cells in animals, and is pursuing FDA approval to conduct clinical trials in humans in 2011.

There were no adverse side effects associated with the device during the study, during which the diabetic pigs receiving the insulin delivery system achieved long-term blood sugar control. Sernova Corporation’s patented Cell Pouch System is implanted under the skin, where it develops into what the company refers to as “a tissue engineered pancreas” when infused with islet cells. The islet cells deliver insulin to the body, much as the islet cells of the pancreas do in people and animals without insulin dependent diabetes. (more…)

Share

Blueberries Improve Insulin Sensitivity

Tuesday, September 21st, 2010

Sixty-seven percent of overweight and pre-diabetic adults who drank two blueberry smoothies a day experienced a ten percent or greater improvement in their insulin sensitivity in just six weeks. The pre-diabetic adults, who were taking part in a study conducted by the Pennington Biomedical Research Center at the Louisiana State University System, had high insulin levels, but not type 2 diabetes. (more…)

Share